Trial Profile
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan (Niacin) for Dyslipidemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Colesevelam (Primary) ; Aspirin; Niacin
- Indications Diabetes mellitus; Dyslipidaemias
- Focus Therapeutic Use
- Acronyms CERTAIN
- 05 Jan 2012 Actual patient number (140) added as reported by ClinicalTrials.gov.
- 16 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 16 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.